Biogen Idec (BIIB)
$226.40
0.00 (0.00%)
BIIB Stock Quote Delayed 30 Minutes
3 Biotech Stocks to Buy That Are Under Severe Pressure
The biotech sector is prone to surprise headlines. But these biotech stocks to buy today have had fallen so much that they hit bottom.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
32.60B
PE Ratio
35.94
EPS
6.3
Volume (Avg. Vol.)
250
Day's Range
-
52-Week Range
$189.44 - $280.41
Dividend & Yield
N/A (N/A)
BIIB Stock Predictions, Articles, and Biogen Idec News
Biogen: Does Aduhelm Make it the Next Dendreon?
Aduhelm was approved by the FDA, priced at $56,000/year, but it isn't a cure for Alzheimer's.
BIIB Stock: The Drug Ban News That Has Biogen Stumbling Today
BIIB stock is losing out today, as two major hospitals have declined to use Biogen's controversial new Alzheimer's drug on their campuses.
New Alzheimer’s Treatment Is A Huge Catalyst for Biogen
BIIB stock was boosted when its Alzheimer's drug was approved. The company's strong financials can sustain the stock's growth.
BIIB Stock: 9 Things to Know About Biogen’s Alzheimer Drug Approval Controversy
Biogen (BIIB) stock is dipping lower today on the additional controversy surrounding the approval of its Alzheimer’s drug, Aduhelm.
Biogen Gets an Unearned Rip on an Unproven Drug
Critics charge the FDA has been compromised and approved Biogen's Alzheimer's drug before it is proven to work.
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
So what did the stock market do today? Investors scrutinized updates to the Colonial Pipeline saga and bet on meme stocks.
4 Top Stock Trades for Tuesday: Bitcoin, BIIB, YETI, COUP
Bitcoin, Biogen, Yeti and Coupa were our top stock trades for Tuesday. Let's take a look at the charts and see how these names are looking.
BIIB Stock Alert: The Huge FDA News That Has Biogen Investors Smiling
Shares of BIIB stock were up to start the day on Monday after the FDA approved the firm's experimental drug to fight Alzheimer’s disease.
14 AI Stocks to Stay Away From
Whether in transportation, manufacturing or healthcare, don't touch any of these 14 AI-related stocks with a 10-foot pole. Here's why.
4 Top Stock Trades for Thursday: BIIB, PTON, GM, WEN
Biogen, Peloton, General Motors and Wendy's were our top stock trades for Thursday. Now, let's look at the charts to see what's going on.
